Last reviewed: June 28, 2026
Last updated: June 28, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide reduces hunger by slowing stomach emptying and signaling fullness to the brain—yet some patients report persistent cravings or difficulty with portion control. This gap between expected and experienced appetite suppression often signals that your current dose, formulation, or treatment strategy needs adjustment to match your individual metabolic needs.
Why Some People Still Overeat While Taking Semaglutide
Semaglutide works by mimicking glucagon-like peptide-1 (GLP-1), a natural hormone that regulates blood sugar and appetite. However, response varies widely—genetic differences in GLP-1 receptor sensitivity, insulin resistance patterns, and dopamine signaling all influence how strongly the medication suppresses hunger. Some individuals start at doses that are too low for their body's needs, while others may experience habituation over time if their dose remains static.
Psychological and behavioral factors also play a significant role. Semaglutide reduces the *physical* drive to eat, but emotional eating, habit-driven snacking, and food cravings rooted in reward pathways may persist. Distinguishing between true hunger and conditioned eating patterns is essential for identifying whether your challenge is physiological or behavioral—or a combination of both.
Genetic Insights Into GLP-1 Response and Appetite Control
Your genes influence how effectively semaglutide works in your body. The PlexusDx Precision Peptide Genetic Test maps genetic variants across 14 appetite and metabolism pathways, including the GLP1R rs6923761 variant, which affects GLP-1 receptor function. Carriers of certain alleles may require higher doses or alternative compounds to achieve the same appetite suppression as others.
Additional genetic markers—such as FTO rs9939609 (linked to hunger hormone sensitivity) and MC4R rs17782313 (involved in central appetite regulation)—reveal whether your overeating tendency stems from heightened hunger signaling or impaired satiety response. Understanding these genetic predispositions allows PlexusDx providers to recommend dose adjustments, formulation switches, or dual-compound protocols tailored to your biology rather than relying on one-size-fits-all approaches.
Dose Optimization and Formulation Choices for Better Appetite Control
Many patients who report continued overeating on semaglutide are simply underdosed. The medication requires titration—gradual dose increases—to reach a therapeutic level suited to your metabolism. If you've plateaued at a low dose, your provider may recommend stepping up to a higher dose within your current tier, or transitioning to a more potent compound like tirzepatide, which activates both GLP-1 and GIP receptors for dual appetite suppression.
PlexusDx offers multiple formulation options to support this optimization. Compounded Semaglutide Injection starts at $149/mo and allows flexible dosing adjustments. If injection discomfort is a barrier, Oral Semaglutide at $249/mo provides an alternative. For patients with inadequate response, GLP-Squared Injection ($249/mo) combines semaglutide and tirzepatide in a single dose, activating more appetite-control pathways simultaneously. Your dose may need to go up. Your price won't.
Behavioral Strategies to Support Medication Effectiveness
Medication alone cannot override learned eating patterns. Pairing semaglutide with structured eating habits—such as eating slowly, identifying true hunger cues, choosing high-protein foods, and reducing exposure to trigger foods—amplifies the medication's effect. Many patients benefit from keeping a food and mood log to distinguish physiological hunger from emotional eating or habit-driven snacking.
Support from a dietitian or therapist familiar with GLP-1 therapy can accelerate progress. These professionals help you build sustainable habits that persist if you ever discontinue treatment, and they identify whether overeating stems from medication factors or lifestyle choices. Combined with genetic testing insights from PlexusDx, behavioral interventions create a comprehensive, personalized weight loss strategy that addresses biology, psychology, and environment.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Why do I still feel hungry on semaglutide?
Hunger persistence on semaglutide often reflects underdosing, genetic variation in GLP-1 receptor sensitivity, or psychological/emotional eating patterns unrelated to physical appetite. PlexusDx providers assess whether a dose increase, formulation switch, or behavioral intervention is needed. The Precision Peptide Genetic Test can reveal genetic appetite-control markers to guide your optimization.
Does the dose matter for appetite suppression?
Yes—dose significantly impacts appetite control. Semaglutide requires gradual titration, and individual response varies based on metabolism and genetics. Many patients who report overeating are undertreated and benefit from dose escalation. PlexusDx supports flexible dosing without price increases, ensuring you reach your therapeutic dose.
What is tirzepatide and how does it differ from semaglutide?
Tirzepatide activates both GLP-1 and GIP receptors, producing stronger appetite suppression and weight loss in many patients compared to semaglutide alone. Compounded Tirzepatide Injection starts at $249/mo. Patients with inadequate response to semaglutide often switch to tirzepatide or dual-compound GLP-Squared Injection for enhanced results.
Can genetic testing predict how well semaglutide will work for me?
PlexusDx Precision Peptide Genetic Test identifies genetic variants in appetite pathways—including GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313—that influence your medication response. This $99 add-on test maps 150+ genetic insights across 14 pathways to personalize your dose, formulation, and behavioral strategy.
Is compounded semaglutide the same as brand-name Ozempic?
PlexusDx compounded semaglutide comes from licensed 503A compounding pharmacies and contains the same active ingredient as brand medications. It is not FDA-approved as a branded drug, but it is legally prescribed and covered by HSA/FSA accounts. Compounded formulations offer flexibility and affordability—Semaglutide Injection starts at $149/mo with no membership fees.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
What You Need to Know About How Much Is Ozempic Per Month
Is Drowsiness a Side Effect of Ozempic?